freenet (OTCMKTS:FRTAF) and Oxford BioMedica (OTCMKTS:OXBDF) are both computer and technology companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, profitability, institutional ownership, dividends and risk.
Volatility & Risk
freenet has a beta of 0.24, suggesting that its share price is 76% less volatile than the S&P 500. Comparatively, Oxford BioMedica has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500.
Earnings & Valuation
This table compares freenet and Oxford BioMedica’s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| freenet | $3.42 billion | 0.72 | $263.53 million | $2.06 | 9.37 |
| Oxford BioMedica | $89.14 million | 5.77 | $9.85 million | $0.15 | 52.20 |
freenet has higher revenue and earnings than Oxford BioMedica. freenet is trading at a lower price-to-earnings ratio than Oxford BioMedica, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current recommendations and price targets for freenet and Oxford BioMedica, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| freenet | 0 | 0 | 1 | 0 | 3.00 |
| Oxford BioMedica | 0 | 0 | 1 | 0 | 3.00 |
Oxford BioMedica has a consensus price target of $14.50, indicating a potential upside of 85.19%. Given Oxford BioMedica’s higher probable upside, analysts clearly believe Oxford BioMedica is more favorable than freenet.
Profitability
This table compares freenet and Oxford BioMedica’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| freenet | 7.71% | 18.18% | 4.89% |
| Oxford BioMedica | N/A | N/A | N/A |
Summary
freenet beats Oxford BioMedica on 6 of the 9 factors compared between the two stocks.
About freenet
freenet AG provides telecommunication, radio and multimedia, mobile communications, mobile Internet, and digital lifestyle services in Germany. It provides a portfolio of services and products primarily in the area of mobile voice and data services. The company offers its postpaid and prepaid services under the mobilcom-debitel brand, as well as no-frills services under the klarmobil, freenetMobile, callMobile, and debitel light brands. It also supplies digital applications related to home automation and security, health, data security, and entertainment and infotainment, including smart phones, tablets, notebooks, and accessories. In addition, the company offers services related to IPTV, including planning, project management, installation, operation, services, and marketing of broadcast-related solutions for business-clients in the radio and media sectors, as well as DVB-T2 services for end users; Freenet TV and waipu.tv in the field of digital motion picture entertainment; payment services for end customers; and digital products and entertainment formats for downloading, displaying, and use on mobile devices. Further, it distributes and sells mobile communications devices and additional services for mobile data communications; and offers e-commerce/advertising services, as well as develops and provides communication and IT solutions, and other services for corporate customers. It operates approximately 530 mobilcom-debitel shops and 43 stores under the GRAVIS brand. The company also sells its products through approximately 400 electronic stores; and online platforms. freenet AG was founded in 2005 and is headquartered in Büdelsdorf, Germany.
About Oxford BioMedica
Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson’s, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes. The company’s products under development include OXB-102 that is in Phase I/IIa study preparation for the treatment of Parkinson’s disease; OXB-202, which is in a Phase I/IIa trial preparation for the prevention of corneal graft rejection; and OXB-302, a gene-based cancer immunotherapy product that has completed pre-clinical development for use in the treatment of a range of cancers, as well as OXB-201 that has completed Phase I trial for the treatment of wet age-related macular degeneration and diabetic retinopathy. It is also developing gene-based therapies, such as SAR 422459 that is in a Phase II trial for the treatment of Stargardt disease; and SAR 421869, which is in Phase I/II trial for the treatment of Usher syndrome 1B. The company has partnerships with Novartis, Sanofi, GlaxoSmithKline, Bioverativ, Orchard Therapeutics, GC LabCell, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations, Immune Design, and Microsoft. Oxford BioMedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
Receive News & Ratings for freenet Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for freenet and related companies with MarketBeat.com’s FREE daily email newsletter.
